- Home
- CUBI vs OGN Comparison
CUBI vs OGN Comparison
Compare CUBI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- OGN
- Stock Information
- Founded
- CUBI 1994
- OGN 1923
- Country
- CUBI United States
- OGN United States
- Employees
- CUBI N/A
- OGN N/A
- Industry
- CUBI Major Banks
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- OGN Health Care
- Exchange
- CUBI Nasdaq
- OGN Nasdaq
- Market Cap
- CUBI 2.3B
- OGN 2.7B
- IPO Year
- CUBI 2012
- OGN N/A
- Fundamental
- Price
- CUBI $64.67
- OGN $7.10
- Analyst Decision
- CUBI Strong Buy
- OGN Hold
- Analyst Count
- CUBI 6
- OGN 4
- Target Price
- CUBI $83.17
- OGN $15.75
- AVG Volume (30 Days)
- CUBI 284.9K
- OGN 9.4M
- Earning Date
- CUBI 10-23-2025
- OGN 11-10-2025
- Dividend Yield
- CUBI N/A
- OGN 1.07%
- EPS Growth
- CUBI N/A
- OGN N/A
- EPS
- CUBI 4.96
- OGN 1.91
- Revenue
- CUBI $651,983,000.00
- OGN $6,301,000,000.00
- Revenue This Year
- CUBI $17.16
- OGN N/A
- Revenue Next Year
- CUBI $13.27
- OGN $0.65
- P/E Ratio
- CUBI $13.04
- OGN $3.90
- Revenue Growth
- CUBI N/A
- OGN N/A
- 52 Week Low
- CUBI $40.75
- OGN $6.18
- 52 Week High
- CUBI $72.51
- OGN $17.23
- Technical
- Relative Strength Index (RSI)
- CUBI 43.06
- OGN 38.12
- Support Level
- CUBI $63.56
- OGN $7.38
- Resistance Level
- CUBI $67.22
- OGN $7.83
- Average True Range (ATR)
- CUBI 1.91
- OGN 0.41
- MACD
- CUBI -0.38
- OGN 0.13
- Stochastic Oscillator
- CUBI 17.37
- OGN 47.74
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.